StockData
Cabaletta Bio, Inc. logo

Cabaletta Bio, Inc. (CABA) stock

CABANasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 2/30
$1.05+0.03 (+3.43%)

Close on Nov 18, 2026Market cap $178.87MP/E –Yield –

Cabaletta Bio free cash flow

Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.

Cabaletta Bio's free cash flow for the twelve months ending Jun 30, 2026 was -$154.21M. For fiscal 2025 it was -$132.31M. The highest annual figure on record is -$16.74M in fiscal 2019.

Annual free cash flow

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$132.31M–
FY2024Dec 31, 2024-$90.43M–
FY2023Dec 31, 2023-$54.24M–
FY2022Dec 31, 2022-$48.83M–
FY2021Dec 31, 2021-$35.28M–
FY2020Dec 31, 2020-$27.41M–
FY2019Dec 31, 2019-$16.74M–

Quarterly free cash flow

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$41.51M–
Q1 FY2026Mar 31, 2026-$42.56M–
Q4 FY2025Dec 31, 2025-$35.55M–
Q3 FY2025Sep 30, 2025-$34.59M–
Q2 FY2025Jun 30, 2025-$30.59M–
Q1 FY2025Mar 31, 2025-$31.59M–
Q4 FY2024Dec 31, 2024-$23.50M–
Q3 FY2024Sep 30, 2024-$20.58M–
Q2 FY2024Jun 30, 2024-$21.56M–
Q1 FY2024Mar 31, 2024-$24.80M–
Q4 FY2023Dec 31, 2023-$16.63M–
Q3 FY2023Sep 30, 2023-$12.67M–
Q2 FY2023Jun 30, 2023-$11.95M–
Q1 FY2023Mar 31, 2023-$12.99M–
Q4 FY2022Dec 31, 2022-$12.45M–
Q3 FY2022Sep 30, 2022-$11.01M–
Q2 FY2022Jun 30, 2022-$12.42M–
Q1 FY2022Mar 31, 2022-$12.96M–
Q4 FY2021Dec 31, 2021-$10.67M–
Q3 FY2021Sep 30, 2021-$8.87M–
Q2 FY2021Jun 30, 2021-$6.97M–
Q1 FY2021Mar 31, 2021-$8.77M–
Q4 FY2020Dec 31, 2020-$9.40M–
Q3 FY2020Sep 30, 2020-$5.19M–
Q2 FY2020Jun 30, 2020-$7.66M–
Q1 FY2020Mar 31, 2020-$5.16M–
Q4 FY2019Dec 31, 2019-$8.16M–
Q3 FY2019Sep 30, 2019-$2.12M–
Q2 FY2019Jun 30, 2019-$4.02M–
Q1 FY2019Mar 31, 2019-$2.45M–

More Cabaletta Bio figures

See a number that looks wrong?